Drug intelligence / Profile preview

Q-1902

Development stage: Preclinical
Lead developer: QureBio

Overview

Q-1902 is a biological product under development by QureBio for the treatment of neoplasms (cancers). The drug is currently in the discovery phase and has not yet entered clinical trials. Its mechanism of action, specific molecular target(s), and detailed modality have not been publicly disclosed. The primary therapeutic area for Q-1902 is oncology, with an active indication listed as "neoplasms." No additional information regarding its structure, route of administration, or further pharmacological details are available at this time[1][2].

Beyond the preview

Go deeper on Q-1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-1902.

Explore the full profile